CuraSen Therapeutics, Inc. is a privately funded biopharmaceutical company pursuing development of novel treatments for psychiatric and neurodegenerative diseases, including depression, Parkinson’s disease and Alzheimer’s disease, as well as certain orphan indications. Millions of patients and their families are burdened by these diseases, and the numbers continue to grow annually with the aging population.
Most approved drugs for depression are associated with undesirable side effects and often take 6-8 weeks to see efficacy. Likewise, approved treatments for Alzheimer’s Disease marginally improve cognitive impairment, and only after 12-24 weeks of treatment and also come with serious side effects. While current treatments for Parkinson’s Disease are initially efficacious in treating motor symptoms, non-motor symptoms of this disease, including cognition, mood and dysautonomias, remain untreated. Despite extraordinary investment in research and development of novel treatments for brain diseases, there is no cure or truly disease-modifying treatment yet identified for any of them.
At CuraSen, we are rethinking the therapeutic approach to treatment of these diseases—and advancing a concept based on restoring a key functionality lost early in the degenerating brain, and also in the aging brain. We are currently developing several treatments that directly activate key receptors in the brain to restore this functionality in diseases in which adrenergic stimulus is inadequate.
CuraSen has assembled an impressive team, deeply experienced in the neuroscience, adrenergic pharmacology, chemistry and clinical development in psychiatric and neurodegenerative disease, as well as top tier and highly committed investor backing, including New Leaf Venture Partners, Longitude Capital, abrdn funds, Intermediate Capital Group (ICG), Alta Partners, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Pappas Capital and the Alzheimer’s Drug Discovery Foundation.